Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Commentary|Articles|September 30, 2026
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Cheney Gazzam Baltz
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
As we gear up for the
Related to this article
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement